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Abstract
Background: Familial hemophagocytosis (FHL) is a rare disease associated with defects in proteins involved in CD8
+ T-cell
cytotoxicity. Hyperactivation of immune cells results in a perilous, Th1-driven cytokine storm. We set out to explore the
regulation of cytokines in an FHL patient who was clinically stable on low-dose immunosuppressive therapy after bone
marrow transplantation over a six-month period. During this period, chimerism analyses showed that the fraction of host
cells was between 1 and 10%. Both parents of the patient as well as healthy volunteers were studied for comparison.
Methods/Principal Findings: Using ELISA, quantitative real-time PCR, and clinical laboratory methods, we investigated
constitutive and inducible cytokines, polymorphisms, and clinical parameters in whole blood and whole blood cultures.
Although routine laboratory tests were within the normal range, the chemokines IP-10 and IL-8 as well as the cytokine IL-
27p28 were increased up to 10-fold under constitutive and stimulated conditions compared to healthy controls. Moreover,
high levels of IFNc and TNFa were produced upon stimulation. Unexpectedly, IFNc induction of IL-18 binding protein (IL-
18BP) was markedly reduced (1.6-fold vs 5-fold in controls). The patient’s mother featured intermediately increased cytokine
levels, whereas levels in the father were similar to those in the controls.
Conclusions/Significance: Since IL-18 plays a major role in perpetuating hemophagocytosis, the failure of IFNc to induce IL-
18BP may constitute a fundamental pathogenetic mechanism. Furthermore, increased production of IL-8 and IL-27 appears
to be associated with this disease. Such dysregulation of cytokines was also found in the heterozygous parents, providing a
novel insight into genotype-phenotype correlation of FHL which may encourage future research of this rare disease.
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Introduction
Hemophagocytic lymphohistiocytosis (HLH), also called hemo-
phagocytic or macrophage activation syndrome, is the name of a
group of rare diseases characterized by a dysregulation of the
immune system. HLH can be inherited, but occurs more
commonly secondary to causes such as viral (including H5N1) or
bacterial infections or cancer. The group of inherited HLH
comprises familial HLH (FHL) and the Che ´diak-Higashi and
Griscelli syndromes, which are associated with various gene
defects, but are nearly identical in clinical presentation. Clinical
features, which are shared by the inherited and the acquired
forms, include nonremitting high fever, hepatosplenomegaly,
cytopenia of at least two lineages, and/or elevations in pro-
inflammatory cytokines and soluble CD25. In severe cases, multi-
organ failure may ensue. Phagocytosis of hematopoetic cells in the
bone marrow, spleen, or lymph nodes caused by dysregulation of
T-cells, NK cells, and macrophages is characteristic of HLH. FHL
usually is manifest in infancy with fulminant failure of several
organs and, without chemo- and immunotherapy followed by
bone marrow transplantation (BMT), is almost always fatal.
Since FHL is rare with 240 reported cases between the first
description by Farquhar and Claireaux in 1952 [1] and 1997 [2],
investigative opportunities are limited. The association of
mutations in the perforin gene with the disease [3] was a
groundbreaking discovery; however, in some patients with acute
FHL, the perforin gene is intact whereas in others the disease
presents late or not at all despite a mutation [4]. To date, five
mutations in genes coding for proteins involved in cytotoxicity of
lymphocytes, namely perforin (causing FHL2), Munc13–4 (FHL3),
syntaxin-11 (FHL4) [5], and STXBP2 (FHL5) [6] have been found
to cause FHL. The gene responsible for FHL1 remains to be
identified. FHL2 to 4 account for about 80% of FHL cases. Recent
studies have further advanced the understanding of the link
between the perforin defect and the cytokine storm of acute HLH,
the latter of which ultimately causes the rapidly progressive multi-
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[8], IL-12 [9], and IL-18 [10–13] are produced at markedly high
levels during the acute phase of the disease. However, more recent
reports have emphasized the particular importance of IFNc and
the subsequent Th1 activation in the pathogenesis of the disease
[10–14]. In fact, levels of free IL-18 are not only elevated [11], but
also correlate with disease severity [13] and may account for
increased expression of IFNc and FasL, as well as for liver
inflammation. High levels of IFNc, which was previously called
macrophage activating factor, may contribute to bone marrow
suppression in HLH.
We therefore investigated parameters of Th1- and general
immune activation in an FHL patient with a perforin mutation.
She was studied for 6 months starting 7 months after BMT during
which a mixed chimerism (1–10% host) was present. We
compared the data to the patient’s heterozygous parents and a
collective of healthy individuals (HC). In addition to demonstrat-
ing dysregulation of several cytokines, we observed that the
induction of IL-18 binding protein (IL-18BP), the only known
natural inhibitor of IFNc and Th1 responses in humans [10,15],
was impaired in the FHL patient’s blood cells.
Materials and Methods
Ethics Statement
Informed written consent was obtained from the patient’s
mother and father as well as from all HC. The experiments were
approved by the Ethikkomission of the J.W.Goethe University and
conducted in compliance with the Helsinki Declaration.
History
At 3 months of age, the female infant was admitted to the
pediatric intensive care unit of the J. W. Goethe University
Hospital at Frankfurt am Main with the classic presentation of
FHL characterized by a sepsis-like clinical picture with hepato-
splenomegaly, pancytopenia, and impaired liver function. FHL
was confirmed by bone marrow histology and FACS analysis
(perforin absent on lymphocytes, G149S mutation). The consan-
guineous parents (first degree cousins) are heterozygotes.
Chemotherapy according to HLH94 [16,17], including etopo-
phos, cyclosporine A, dexamethasone, and intrathecal methotrex-
ate was initiated 4 days after admission and the initial response was
good. At 6 months of age, the patient underwent BMT using
marrow from an HLA (high resolution)-identical donor. Hema-
topoetic recovery was adequate. Post-BMT complications includ-
ed one episode of graft-versus-host disease of the skin on days 20 to
25, which quickly remitted under short-term prednisolone.
The patient was in good overall condition and chimerisms were
between 1 and 10% host cells during study period. Informed
written consent was obtained from the patient’s mother and father
as well as from all HC. All experiments were conducted in
compliance with the Helsinki Declaration.
Reagents
Chemicals, reagents and kits were obtained from the following
companies: E. coli-LPS (O127:B8): Sigma, Munich; IFNc:
Peprotech, Frankfurt; RPMI 1640 medium and FCS: Life
Technologies GibcoBRL, Karlsruhe; IL-8 and IP-10 ELISA kits:
BD Pharmingen, Heidelberg; all Germany. PCR reagents and
devices: Applied Biosystems, Foster City, CA, USA.
Whole Blood (WB) Culture
Equal volumes of freshly obtained heparinized blood were
mixed with RPMI1640 plus 25 mM Hepes, 100 U/ml penicillin,
and 100 mg/ml streptomycin. 1 ml aliquots were then transferred
into round-bottom polypropylene tubes which were incubated at
37uC and 5% CO2 for 20 h.
Detection of Cytokines
WB cultures were mixed, then one aliquot was lysed with Triton
X-100 (final concentration 1%) for determination of IL-8. The
other aliquot was centrifuged at 350 g and the cell-free
supernatant was removed and assayed for IP-10. ELISAs were
performed according to the manufacturer’s instructions.
Isolation of RNA and PCR
Total RNA from WB cultures was obtained using the
QIAamp RNA Blood Mini Kit from Qiagen (Hilden,
Germany). Primers and probe for IL-18BPa real-time PCR
were as follows: primers, 59-acctcccaggccgactg-39 and 59-
ccttgcacagctgcgtacc-39;p r o b e ,5 9-caccagccgggaacgtggga-39 (ex-
on/intron spanning). For GAPDH, pre-developed assay re-
agents (Applied Biosystems) were used. Specificity of PCR
products was tested by classic PCR using the aforementioned
primers. mRNA copy numbers for IL-18BPa and GAPDH were
determined using cloned cDNA standards. For analysis of IL-
27p28, 35 cycles of a PCR with the primers 59-gcggaatct-
cacctgccag-39 and 59-cgggaggttgaatcctgca-39 were run.
Cytokine Promoter Analysis
Variant alleles of the cytokine promoters IL-6 (G-174-C), IL-8
(A252T), and TNFa (G-308A) were performed as described in
detail previously [18,19].
Statistical Analysis
Data were analyzed by Student’s t-test.
Results
Elevated Cytokine Levels in WB of Family Members
Chimerism studies indicated that during the time of these
investigations, 1 to 10% of blood cells were of host origin. The
ability of the patient’s whole blood to produce Th1 and effector
cyto-/chemokines under steady-state as well as stimulated
conditions was compared to that in phenotypically healthy
heterozygotes, namely both parents, as well as to that in HC.
As shown in Figure 1A and B, the average basal production of
IP-10 and IL-8 during the study period was markedly increased in
the FHL patient compared to HC. Both chemokines were also
significantly elevated in the patient’s mother; IP-10 was increased
in the father. In contrast, constitutive production of IFNc and
TNFa was similar in each subject (panels C and D).
Upon stimulation with LPS, WB cultures from mother, father,
and HC secreted comparable amounts of IP-10, TNFa, and IFNc
protein (Figure 2), whereas the patient produced considerably
more IP-10 (5-fold), TNFa, and IFNc (both 3-fold). IL-8 release
after LPS in the patient was more than 10-fold higher than in HC.
The mother also produced significantly more IL-8 than father and
controls. She featured a similar pattern for IFNc when IL-12 was
used as an additional stimulus (panel D).
In family members and in HC, constitutive levels of IL-6
were below detection limits (5 pg/ml) and measurements of CRP,
white blood count including differential IgG, IgA, and IgM, LDH,
and kidney function were each within normal limits throug-
hout the study period. Only parameters of liver function,
namely ALT, AST, and cGT, were slightly elevated in the
patient.
IL-18BP in FHL
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Identical genotypes of the promoters of the IL-8 and TNFa
genes were found in the mother, father, and the patient
(heterozygous AT for IL-8, homozygous for allele A for TNFa).
The same was the case for FccRIIa and IIIb. For IL-6, the father
was heterozygous, whereas both patient and mother were
homozygous for allele G, which is associated with a higher
production of the cytokine [20].
Dysregulation of Anti-Inflammatory IL-18BP and IL-27p28
Despite immunosuppressive therapy, markedly increased levels
of several pro-inflammatory cytokines were produced in WB
cultures from the patient. We next investigated two anti-
inflammatory mediators, IL-18BP and IL-27. It is known that
IFNc is a potent inducer of IL-18BP in vitro [21] as well as in
patients treated with IFNa [22]. Although steady-state expression
of IL-18BP in whole blood was moderately elevated in the patient
(Figure 3A), the induction of IL-18BP by IFNc was greatly
reduced compared to HC (1.6-fold vs 5-fold, panel B). Whereas
IL-18BP expression in the father’s cells was nearly identical to that
of the controls, the cells of the mother exhibited intermediate
steady-state and IFNc-induction patterns. In contrast to IL-18BP,
steady-state expression as well as IFNc-induction of IL-27p28 was
markedly higher in the patient than in the parents and in HC
(Figure 3C).
Discussion
Previous studies have revealed a pivotal role for Th1 cytokines in
patients with FHL. For instance, antibodies to IFNc, but not to
other cytokines, improved the course of the disease including
survival in an animal model of FHL [14]. In patients, IL-18 [11–13]
and IFNc [13] correlate with disease severity. Although both IL-
18BP and IP-10 were elevated in WB cultures from our patient
under steady-state conditions, the near absent induction of the Th1
antagonist IL-18BP by IFNc was striking. In contrast, LPS-induced
increases in the pro-inflammatory chemokines IP-10 (14-fold) and
IL-8 (20-fold) were comparable to or even greater than in control
subjects. This suggests the conclusion that, despite BMT and
immunosuppression, regulation of IL-18BP is severely impaired in
the FHL patient. The induction of IL-18BP by interferons,
demonstrated by Paulukat et al in vitro [21], by Kaser et al in
vivo [22], as well as the characterization of the IFNc-responsive
promoter [23,24] each constitute a negative-feedback loop to
reduce IFN activity and the subsequent Th1 responses [10]. Hence,
our data appear to reveal a fundamental pathophysiological
mechanism of HLH, that is, escape of IL-18BP from IFNc
stimulation. Consistent with this concept is the observation that in
secondaryHLH,lowlevelsofIL-18BPresultinhighfreeIL-18[11].
Of note, IL-18BP also reduces inflammation caused by IL-18
directly, i.e. independent of IFNc. This fact should be taken into
account when the results of two other studies are contemplated, in
whicha dysregulationofthe IL-18/IL-18BPequilibriuminsystemic
lupus erythematosus (SLE) [25] and Wegener’s granulomatosis
(WG) [26]wasreported. In fact, analysis of the responsiveness of IL-
18BP production to IFN stimulation may be a worthwhile topic of
research in SLE and WG.
Our patient was in good general condition and most laboratory
parameters were normal, but she featured an incomplete
chimerism and slightly elevated liver enzymes. These clinical
findings were accompanied by a pro-Th1 twist of steady-state and
inducible cytokine levels. Unexpectedly, cytokine production
abnormalities were also detectable both healthy parents, with the
mother resembling the patient at a smaller scale, but the father
showing only slight abnormalities. Individuals heterozygous for
perforin mutations have previously been studied regarding the
activity of their NK cells [4,27,28], but changes in cytokine levels
have not been reported before. Although the molecular mecha-
nisms for the differences in the parent’s cytokine regulation
patterns remain unclear, these differences are in accord with
varying degrees of NK cell function in heterozygotes [27,28].
Taken together, the findings in the patient (which likely indicated a
smoldering disease state) and in the parents establish a novel
vantage point from which the genotype-phenotype correlations of
FHL can be investigated in future studies.
Based on data in perforin-deficient mice [14], the pathophys-
iology of FHL might include presentation of a foreign (e.g. viral)
Figure 1. Excessive cytokine production in WB cultures from
the FHL patient. WB culture were incubated for 20 h; thereafter, ELISA
was performed on lysates (IL-8) or supernatants (others). Data are
shown as cytokine protein in pg normalized to 1 million white blood
cells 6 SEM, n=4 time points for IP-10 and IL-8 and n=3 for IFNc and
TNFa spanning 6 months for all subjects; the same three healthy donors
were tested on each time point. *, p,0.05 and **, p,0.01 for healthy
controls vs patient, mother, and father; #,p ,0.05 and ##,p ,0.01 for
patient vs mother and father.
doi:10.1371/journal.pone.0008663.g001
IL-18BP in FHL
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CD8
+ T-cells. Besides attempting to kill infected cells via perforin,
activated CD8
+ T-cells secrete cytokines, including IFNc. Since
CD8
+ T-cells from patients with perforin-associated FHL fail to
kill infected cells, these killer cells continue to activate macro-
phages and to deliver proliferation signals to T-cells. In turn, T-
cells and macrophages perpetuate the production of mostly Th1
and pro-inflammatory cytokines and, in the case of macrophages,
uncontrolled phagocytosis is initiated [29]. However, it is
important to bear in mind that this animal model has its
limitations: a) the observations are based on infection with one
virus; a different infectious agent may produce different results. b)
Not every case of human FHL/HLH is caused by a perforin
mutation - defects in other proteins can elicit a similar clinical
picture although there may be differences in pathophysiology. c) It
appears unlikely that CD8
+ T-cell-derived IFNc is the only factor
which drives the deleterious inflammation in humans. IFNc may
be produced by other cells and, most importantly, macrophages
likely play a more prominent role, since IL-18 is closely related to
disease severity in human FHL/HLH [11–13]. Macrophage-
derived IL-18 may in fact bypass IFNc, directly causing
inflammation. These properties of IL-18 may help explain why
this cytokine appears more critical than others, e.g. IL-12 [13], to
the pathogenesis of FHL/HLH and highlight the importance of
the dysregulation of IL-18BP for the disease process. We suggest
that IL-18BP deserves consideration as a therapeutic agent in
diseases in which a dysregulation of the IL-18/IL-18BP equilib-
rium is evident. This is the case in SLE [25] and WG [26] and,
although our observations need to be confirmed in larger cohorts,
FHL and secondary HLH are also candidate diseases.
In accord with the pathophysiological processes described
above, the chronic low-level activation of the Th1 system in our
patient (moderately elevated steady-state levels of IP-10 and IL-
18BP, but not of TNFa) may result from the persistent stimulation
delivered by the host’s own, perforin-deficient cells. Interestingly, a
similar mechanism appears to be involved in the pathogenesis of
influenza caused by the H5N1 virus, as the H5 hemagglutinin
suppresses perforin expression [30] which essentially results in an
acquired form of HLH, including dysregulation of cytokines
[31,32]. Furthermore, some viruses encode secretable IL-18BP
which interferes with the host’s immune response by reducing free
IL-18. For example, the lesions caused by molluscum contagiosum
virus are nearly void of inflammatory cells [33].
An association of IL-8 with HLH has been described for the
secondary [34], but not the familial disease. Neutrophils are not
considered a first-line problem in FHL; however, pathological
neutrophil behavior can occur in related clinical situations [35,36].
As IL-8, which was markedly elevated in our patient, aggravates
inflammation by recruiting neutrophils to sites of active disease,
our data indicate that the role of neutrophils in HLH may be
underappreciated.
Presently, there is no link of IL-27 to HLH. This cytokine can
promote a Th1 response in its early stages [37] and thus may
contribute to disease progression in FHL. On the other hand, the
predominant function of IL-27 is anti-inflammatory (e.g.,
inhibition of Th2, Th17, and late-stage Th1 responses, as well
Figure 2. Cytokine levels in WB cultures stimulated with LPS. WB cultures were incubated in the presence of 100 ng/ml LPS for 20 h. In panel
D, IL-12 (20 ng/ml) was also added. IL-8 was measured in cell lysates, IP-10, TNFa, and IFNc were determined in the supernatants. Data are depicted
as cytokine protein in pg normalized to 1 million white blood cells 6 SEM, n=4 time points for IP-10 and IL-8 and n=3 for IFNc and TNFa over a
period of 6 months for all subjects; the identical healthy volunteers were tested on each time point. *, p,0.05 and **, p,0.01 for healthy controls vs
patient, mother, and father; #,p ,0.05 and ##,p ,0.01 for patient vs mother and father.
doi:10.1371/journal.pone.0008663.g002
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upregulation of IL-27 may constitute one of the negative feedback
mechanisms which are commonly initiated in response to
inflammation. It is possible that IL-27 is partially effective in
reducing the severity of the disease in the patient, achieving a
healthy phenotype, but failing to restore an entirely normal status
of the immune system.
Our data are obtained from a single patient and her parents;
thus, any conclusion needs to be drawn with reasonable caution.
We anticipate that this limitation may encourage future research
to corroborate our findings and elaborate on several aspects,
especially on a possible therapeutic role of IL-18BP in HLH.
Summarizing our data, we suggest that assessing IL-18BP, IP-10,
and/or IL-8 may assist in identifying latent disease activity in
transplanted FHL patients whose clinical condition and laboratory
status is still normal. IL-8 and IL-27 are introduced as possible
new players in FHL. Furthermore, different degrees of abnormal-
ities of cytokine regulation in the heterozygous parents shed light
on genotype-phenotype correlations in FHL. Most importantly,
we assert that the capacity of IL-18BP to counterbalance excessive
production of Th1 cytokines was defective in the patient. This may
constitute a novel mechanism of disease perpetuation which, given
the pathogenetic similarities, may also be relevant in SLE, WG,
and H5N1 infections.
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